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Abstract
cAMP-mediated PKA signaling is the main known pathway involved in maintenance of the endothelial barrier. Tight
regulation of PKA function can be achieved by discrete compartmentalization of the enzyme via physical interaction with A-
kinase anchoring proteins (AKAPs). Here, we investigated the role of AKAPs 220 and 12 in endothelial barrier regulation.
Analysis of human and mouse microvascular endothelial cells as well as isolated rat mesenteric microvessels was performed
using TAT-Ahx-AKAPis peptide, designed to competitively inhibit PKA-AKAP interaction. In vivo microvessel hydraulic
conductivity and in vitro transendothelial electrical resistance measurements showed that this peptide destabilized
endothelial barrier properties, and dampened the cAMP-mediated endothelial barrier stabilization induced by forskolin and
rolipram. Immunofluorescence analysis revealed that TAT-Ahx-AKAPis led to both adherens junctions and actin cytoskeleton
reorganization. Those effects were paralleled by redistribution of PKA and Rac1 from endothelial junctions and by Rac1
inactivation. Similarly, membrane localization of AKAP220 was also reduced. In addition, depletion of either AKAP12 or
AKAP220 significantly impaired endothelial barrier function and AKAP12 was also shown to interfere with cAMP-mediated
barrier enhancement. Furthermore, immunoprecipitation analysis demonstrated that AKAP220 interacts not only with PKA
but also with VE-cadherin and ß-catenin. Taken together, these results indicate that AKAP-mediated PKA subcellular
compartmentalization is involved in endothelial barrier regulation. More specifically, AKAP220 and AKAP12 contribute to
endothelial barrier function and AKAP12 is required for cAMP-mediated barrier stabilization.
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Introduction
The vascular endothelium lining the intima of blood vessels
precisely regulates the passage of solutes, macromolecules, and
leukocytes between the blood and the underlying tissue. Under
inflammatory conditions, mainly in post-capillary venules, loss of
this primary function leads to formation of intercellular gaps and
increased vascular permeability. The latter is a hallmark of several
pathological processes (i.e. inflammation, allergy, arteriosclerosis,
edema, tumor growth and sepsis) and contributes to multi-organ
failure and death [1,2]. Therefore, understanding of the mecha-
nisms maintaining endothelial barrier functions under resting
conditions, as well as the signaling pathways leading to barrier
impairment or recovery are of great biological and clinical
importance.
Paracellular permeability is tightly regulated by coordinate
opening and closing of mainly two types of endothelial cell-cell
junctions, namely tight junctions (TJs) and adherens junctions
(AJs). While TJs seal the intercellular cleft between cells, the AJs
are providing mechanical strength. However, the junctional
composition of intracellular clefts varies across the vascular tree
[3]. Both junctional types are composed of transmembrane
proteins, i.e. the tight junction protein claudin-5 and the adherens
junction protein VE-cadherin. These junctional markers are
associated with the cortical actin cytoskeleton via several adaptor
molecules such as zonula occludens (ZO) proteins and catenins,
respectively [4]. Numerous studies showed that modulation of
endothelial barrier functions via actin cytoskeleton remodeling and
cell junction integrity can be controlled by members of the Rho
family of small GTPases, i.e. RhoA, Rac1 and Cdc42 as well as by
the Ras family GTPase Rap1. Although it is suggested that fine
balance between activation and/or inactivation of these small
GTPases is required for barrier maintenance, it is generally
assumed that activation of RhoA impairs barrier function, while
Rac1 and Cdc42 are considered to primarily stabilize barrier
integrity [1,5,6,7]. It is now widely recognized that a number of
barrier-stabilizating mediators activate Rac1 either directly or
indirectly via an increase in the concentration of the cellular
second messenger cAMP. cAMP- dependent Rac1 activation can
be achieved by both, exchange protein activated by cAMP1
(Epac1)/Ras-related protein 1 (Rap1), and cAMP-dependent
protein kinase A (PKA) signaling pathways. The latter is generally
believed to be the predominant cAMP mechanism that exerts
significant protection against the increase in endothelial para-
cellular permeability [8]. Furthermore, it is assumed that precise
spatiotemporally regulated activation is essential for the response
specificity of the PKA pathways. Thus, it was found that a key role
in tight regulation and compartmentalization of PKA-dependent
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signaling is played by A kinase-anchoring proteins (AKAPs) [9].
AKAPs are a large structurally diverse family of functionally
related proteins that contain a conserved amphipathic helix PKA
binding motif and function to localize PKA-AKAP complexes at
discrete compartments within the cell such as plasma membrane,
endoplasmic reticulum, mitochondria or Golgi complex [10]. By
anchoring the inactive PKA to defined cellular sites, AKAPs allow
specific placement of the holoenzyme at regions of cAMP
production and thus to propagate confined phosphorylation of
only a subset of potential substrates located in close proximity.
AKAPs are also scaffolding proteins tethering not only PKA, but
also other molecules involved in cAMP signaling such as adenylyl
cyclases (ACs), phosphodiesterases (PDEs), Epac1, which is
guanine nucleotide exchange factor (GEF) of Rap1 and protein
phosphatases [11,12,13,14,15,16]. Thus, AKAP complexes assem-
ble PKA with a determined set of signal transduction (i.e. kinases)
and termination (i.e. phosphatases, phosphodiesterases) molecules
as well as with a variety of other members of different signaling
pathways. Therefore, AKAPs organize crosstalk across diverse
paths in the cell’s signaling networks [9,17].
Although the protective effects of cAMP/PKA signaling for
endothelial barrier regulation are well recognized, it is not yet
clear by which mechanisms PKA is located close to cell junctions.
Based on our previous investigations, we speculated that
compartmentalized cAMP-signaling by AKAPs contribute to
endothelial barrier integrity. Thus, we investigated the importance
of AKAP function for maintenance of the cAMP/PKA-dependent
endothelial barrier in vivo and in vitro.
In order to modulate AKAP function, we used a modified
analog of a cell-permeable synthetic peptide designed to compet-
itively inhibit PKA-AKAP interaction [18]. This peptide, named
TAT-Ahx-AKAPis, is comprised of two functional peptides, TAT
and AKAPis, connected via an aminohexanoic (Ahx) linker.
AKAPis is a precisely designed sequence with high-affinity binding
and specificity for the PKA regulatory subunit (RII) which enables
a higher dissociation effect on the PKA-AKAP anchoring than the
widely used Ht31 synthetic peptides [18]. The second functional
unit, commonly denoted as TAT, is a cell-penetrating peptide
derived from the TAT protein of human immunodeficiency virus
(HIV-1). The TAT peptide possesses a high ability to mediate the
import of membrane-impermeable molecules such as DNA, RNA,
peptides and even whole proteins into the cell [19].
Although approximately 50 AKAPs have been identified in
different cell types, little is known about the AKAP expression
profile and function in endothelial cells. In the current investiga-
tion, besides AKAP12, which has already been found in
endothelium and its involvement in regulation of endothelial
integrity has been reported [20,21,22,23], we focused on
AKAP220. The latter was recently shown to contribute to the
integrity of the cortical actin cytoskeleton [24], but was also
suggested to link cAMP signaling to cell adhesion [25]. Both
AKAP220 and AKAP12 are expressed in endothelial cells
according to microarray data published in GeneCards database
(http://www.genecards.org/).
In this study, by using in vivo and in vitro techniques, we
provide evidence that AKAP-mediated PKA subcellular compart-
mentalization contributes to endothelial barrier integrity. Our data




Human Dermal Microvascular Endothelial Cells (HDMECs)
were obtained from PromoCell (Heidelberg, Germany). The cells
were grown in Endothelial Cell Growth Medium MV containing
supplement mix provided by the same company. Passage of the
cells was performed by using Detach kit (PromoCell). All
experimental procedures were carried out with HDMEC from
passage 2 to 5 [26]. Additionally, an immortalized microvascular
endothelial cells (MyEnd), previously isolated from murine
myocardial tissue were used for the experiments. Cell generation
and characterization have been described elsewhere [27,28]. Cells
were cultured in DMEM (Life Technologies, Karlsruhe, Ger-
many), supplemented with Penicillin G/Streptomycin (50 U/ml)
(Sigma-Aldrich, Munich, Germany) and 10% Fetal Calf Serum
(FCS) (Biochrom, Berlin, Germany).
Both cell types were cultured at 37uC in a humidified
atmosphere of 5% CO2.
Antibodies and test reagents
The polyclonal rabbit anti-PKA RII alpha (sc-908) and the goat
anti-VE-cadherin (sc-6458) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, U.S.A.). Detection of VE-
cadherin in MyEnd cells was performed by using rat anti-VE-
cadherin mAb (clone 11D4.1; undiluted hybridoma). The mouse
monoclonal anti-PKA RII beta (Cat.# 610625) and anti-ß-catenin
(Cat.# 610154) antibodies were obtained from BD Biosciences
(Franklin Lakes, U.S.A.). The mouse monoclonal anti-AKAP12
antibody (ab49849) was acquired from Abcam (United Kingdom).
The rabbit polyclonal anti-AKAP220 antibody was kindly
provided by John Scott (Howard Hughes Medical Institute,
Department of Pharmacology, University of Washington School of
Medicine).
To increase cAMP levels, Forskolin (F), (Cat.# F6886) and
Rolipram (R), (Cat.#R6520) purchased from Sigma-Aldrich (St.
Louis, U.S.A.) were used in combination for 1 hour at
concentrations of 5 and 10 mM, respectively. In addition, cell-
permeable synthetic peptide TAT-Ahx-AKAPis
(GRKKRRQRRRXQIEYLAKQIVDDNAI) was utilized to
competitively inhibit the interaction between the PKA regulatory
subunit II (RII) and AKAPs. By using the ECIS system,
preliminary concentration- effect experiments determined the
effectiveness of the peptide on endothelial barrier stability (data
not shown). The analysis revealed that 30 mM inhibitory peptide,
dissolved in sterile distilled water with 10% DMSO, is the most
effective peptide concentration for modification of endothelial
barrier integrity. In parallel, experiments were conducted with
TAT-Ahx-mhK77 scrambled synthetic peptide
(GRKKRRQRRRXQFSSQSAFSSRSRRARS). The latter is
similar to the inhibitory peptide regarding molecular weight,
isoelectric point and amino acid composition. Both peptides were
synthesized by Peptide Specialty Laboratories GmbH (Heidelberg,
Germany). Simultaneously, a control condition (vehicle) was run.
This internal control is composed of medium containing DMSO
in a concentration corresponding to the one used for dissolving the
peptides.
Rac1 activation assay
To quantify the levels of Rac1 activity in cells, a Rac G-Lisa
Activation Assay Biochem Kit (Cytoskeleton, Denver, CO;
Cat.#BK126) was used. Briefly, confluent monolayers of
HDMEC and/or MyEnd cells were incubated either in the
absence or the presence of TAT-Ahx-AKAPis. Parallel adminis-
AKAPs in Endothelial Barrier Regulation
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tration of scrambled TAT-Ahx-mhK77 peptide was carried out.
Besides F/R application, vehicle was applied as an additional
control. Cells were lysed and the lysates were processed according
to the manufacturer’s instructions. The absorption was measured
at 490 nm using a TECAN, Infinite 200 PRO microplate reader
(Tecan, Austria).
Figure 1. TAT-Ahx-AKAPis significantly reduced microvascular endothelial barrier function and reverted F/R- mediated barrier
stabilization. TER measurements were carried out to monitor endothelial barrier alterations in response to different mediators and synthetic
peptides. (A) displays the time course of TER measurements under various experimental conditions for HDMEC. The first arrow indicated the time
point of TAT-Ahx-AKAPis and/or TAT-Ahx-mhK77 addition. 1 hour after the first application, F/R was added (second arrow). (B) summarizes the results
after 600 min, the time point at which the monitored effects reached their peaks. TAT-Ahx-AKAPis significantly decreased TER compared to control/
vehicle condition and treatment with scrambled peptide (TAT-Ahx-mhK77) starting at 80 min after application for HDMEC. F/R addition resulted in
pronounced and continuous increase of TER after 1 hour. A similar effect was detected after pre-incubation with TAT-Ahx-mhK77 scrambled peptide.
In contrast, 1 hour pre-treatment with TAT-Ahx-AKAPis initially reduced, but subsequently did not abolished the effect of F/R. (C) To further test the
effect of TAT-Ahx-AKAPis on F/R- mediated enhancement of endothelial barrier function, HDMEC cells were exposed to F/R for 1 hour (first arrow) and
post- incubated with TAT-Ahx-AKAPis inhibitory peptide (second arrow). (D) graphically represents the statistical outcome of the data presented in
panel (C). Based on ANOVA multiple analysis, the most significant peaks of the monitored effects were determined at 1000 min. At that time point
(1000 min), the similarly responding TAT-Ahx-AKAPis- and F/R+TAT-Ahx-AKAPis- cell monolayers displayed TER significantly lower than the one in
control monolayers. In contrast, F/R- mediated enhancement in TER remained constant over time. Data were collected from more than three
independent experiments (N $3, n$4–10). *** p#0.001, ** p#0.01, * p#0.05, indicate statistically significant difference between examined groups.
n.s. – not significant.
doi:10.1371/journal.pone.0106733.g001
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Measurement of transendothelial resistance (TER)
An ECIS Z Theta system (Applied Biophysics Inc, Troy,
U.S.A.) was used to assess the endothelial barrier integrity of
confluent and subconfluent cell monolayers as previously de-
scribed [29]. In short, the cells were grown to confluency on gold
microelectrodes 8W10E+ (Ibidi, Germany, Cat.# 70040). MyEnd
were seeded on gelatin-coated gold electrodes, HDMEC were
grown on uncoated arrays. HDMEC cells reached confluency in
between 8 to 10 days, while MyEnd formed a confluent monolayer
within 3 to 4 days. Directly before the experiment, the medium
was exchanged and the arrays were mounted onto the holders of
the ECIS system, placed in an incubator (37uC, 5% CO2). For
both cell types, the optimal frequency to analyze the changes in the
transendothelial resistance was identified as 4000 Hz. After short
equilibration for approximately 15 to 20 min, the baseline
resistance was recorded for another 15 min, followed by applica-
tion of the test reagent to each well yielding a final well volume of
400 ml.
For some experiments, the effect of AKAPs on endothelial
barrier formation was tested by TER measurements initiated in
subconfluent cell monolayers transiently transfected with specific
siRNA. Cell confluency was determined by a light microscopy,
subsequently the basal transendothelial electrical resistance was
measured by ECIS system. Subconfluent MyEnd cells had a basal
resistance of 550 to 800 ohm. The resistance monitored in
confluent cell monolayers was above 800 ohm and reached values
of approximately 1400 ohm.
Immunoprecipitation (IP) and Western blot (WB) analysis
MyEnd cells were grown to confluence. After quick washing
with ice-cold PBS, the cells were incubated for 10 min with pre-
chilled precipitation buffer (0.5% Nonidet-40, 10 mM HEPES
(pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 5 mM EDTA), to which
cOmplete protease inhibitor cocktail (Cat.# 11697498001,
Roche) was freshly added. Cells were scraped and the homoge-
nized suspension was clarified by centrifugation at 6000 g for
5 min, at 4uC. The supernatant was transferred to a fresh reaction
vial and the protein concentration was estimated using the
Bradford assay [30]. For immunoprecipitation with either rabbit
anti-PKA or goat anti-VE-cadherin antibodies, cell lysates with
400–600 mg of total protein amount were pre-cleaned (for 1 hour
at 4uC) by incubation with Protein G Plus-Agarose (Calbiochem
Merck, Darmstadt, Germany Cat.#IP08). The resulting superna-
tant was incubated for 3 hours at 4uC with 1, 5 mg of defined
antibody. To each sample, 25 ml of beads were added and
overnight incubation at 4uC on a rocker platform was carried out.
The beads with attached immunoprecipitated complexes were
collected by centrifugation at 6000 g for 2 min, washed 3 times
with cold washing buffer (0,05% Nonidet-40, 10 mM HEPES
(pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 5 mM EDTA) and
resuspended in Laemmli buffer. Boiling at 95uC for 5 min serves
to denature proteins and detach them from the beads. The
immunoprecipitated complexes were separated on a SDS-PAGE
gel, transferred to a nitrocellulose membrane and analyzed by
Western blot (WB) assay [29]. The AKAP220 antibody was used
in 1:500 dilution, detection of AKAP12 was done with antibody
diluted 1:5000. All other antibodies were used in 1:1000 dilution.
Secondary antibodies were diluted 1:3000.
ImageJ software was used to quantitatively assess the Western
blot data. Same size rectangular areas were drawn around each
band of interest and the signal intensity within the area was
measured. Similarly, the fluorescence intensity determined at
identically sized rectangles surrounding regions under or above the
bands served as background. For the immunoprecipitation
experiments, subtraction of the intensity determined within the
control IP (IP: Beads, no Ab) was performed as well. Then the
signal intensity was normalized either to the fluorescence intensity
of housekeeping proteins (loading control) or to the intensity of the
protein used to pull down desired protein complex. In order to
combine all experiments, the data were presented as percent of
control.
Immunofluorescence (IF) analysis
Detailed description of the assay was previously published [29].
In short, HDMEC were cultured to confluency on uncoated glass
cover slips. Control cells or cells treated with different test reagents
as specified below were washed with PBS, fixed with 2%
formaldehyde for 10 min at room temperature (RT) and, after
washing with PBS, were permeabilized with 0,1% Triton X-100 in
PBS. The adherent cell monolayer was blocked for an hour with
10% normal goat or donkey serum in 1% BSA/PBS followed by
overnight incubation at 4uC with primary antibodies. After
washing with PBS, the respective secondary antibodies conjugated
with Cy3 (1 hour, RT) were applied. In addition, for visualization
of filamentous actin, 1:100 diluted ALEXA488-conjugated–
phalloidin was added to the secondary antibody. Images were
obtained by using a confocal microscopy setup (Leica SP5,
Mannheim and Wetzlar, Germany) equipped with a HCX PL
APO Lambda blue 63x 1.4.oil objective (Leica), with the same
settings for all conditions tested.
Quantification of protein distribution was carried out using
ImageJ computer software. For intensity determination, a rectan-
gle was drawn over more than 15 randomly chosen areas of
HDMEC plasma membrane in at least three independent
experiments. The mean intensity distribution of proteins examined
was recorded for each depicted rectangle. A region next to the cell
without specific fluorescence was selected as the respective
background. In order to combine and compare all immunofluo-
rescence experiments, the data was presented as percent of control
(vehicle).
Transfection with small interfering RNA (siRNA)
Down-regulation of mouse specific AKAP12- and AKAP220
mRNA was obtained by using ON-Target SMARTpool siRNA
(Dharmacon Thermo Fisher Scientific, Waltham, U.S.A.; Cat.#
L-046094-00-0005371,00 and Cat.#L-048015-00-0005, respec-
tively). As a negative control, ON-TARGET plus Non-Targeting
siRNAs (Dharmacon, Cat.# D-001810-10-20) was applied. The
siRNA was delivered into the cells by applying TurboFect in vitro
transfection reagent (Fermentas, St. Leonrot, Germany, Cat.#
R0531). The transient transfection was carried out according to
the manufacturer’s protocol. Briefly, after 20 min pre-incubation
at RT, the transfection solution composed of TurboFect, siRNA
and serum- free DMEM was diluted into serum-containing
medium and added dropwise to MyEnd cells with 60–70%
confluence. 48 hours after transfection, AKAPs-depletion was
confirmed by Western blot.
For ECIS-based measurements, MyEnd were transfected with
specific siRNA at 70% confluency. 24 hours after transfection
medium was exchanged and TER was monitored. Basal and
cAMP- stimulated Rac1 activities were examined 48 hours after
siRNA transfection in control cells or cells treated with F/R,
respectively.
AKAPs in Endothelial Barrier Regulation
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Animal preparation and measurement of hydraulic
conductivity (Lp) of the microvessel wall
A detailed description of the animal preparation and the
microvessel Lp measurements was reported elsewhere [27,31]. All
experimental protocols and procedures were consistent with the
requirements of the National Institute of Health ‘‘Guide for the
Care and the use of Laboratory Animals’’ and approved by
Government of Lower Franconia (Az 55.2-2531.01-24/09). Wistar
rats (Charles River Laboratories, Sulzfeld, Germany), with body
weight ranging from 250 to 450 g, were anesthetized by
subcutaneous injection of pentobarbital sodium at a dose of
65 mg/kg. The anesthetic substance and its way of application
were chosen not to interfere with blood vessel permeability. In
addition, depth of anaesthesia was checked regularly by animal’s
reaction to foot pad pinching. Supplemental anaesthetic was given
only if the above mentioned reaction was positive. The experi-
ments were carried out using straight, non-branched segments of
mesenteric venular microvessels (25 to 35 mm in diameter). As
descried earlier, the Lp measurements of the microvessel wall are
based on the modified Landis technique, which measures the
volume flux of fluid per unit surface area of the vessel (Jv/S), which
was canulated with a glass micropipette and occluded in advance
[32,33]. During measurements, the hydraulic pressure of usually
50 cm H2O was constant with the assumption that the net
effective pressure determining fluid flow (Peff) was equal to the
applied hydraulic pressure minus 3 cm H2O (the approximate
oncotic pressure contributed by BSA in all perfusates (10 mg/ml))
[27]. For each occlusion, Lp was estimated as (Jv/S)/Peff. All
perfusates were mammalian Ringer’s solution containing 10%
BSA (Sigma-Aldrich) with or without TAT-Ahx-AKAPis inhibi-
tory synthetic peptide. Measurements were performed every
10 min for up to 120 min in the presence and absence of the
synthetic peptide. Each animal was used for a single experiment
only. After experimental completion, the unconscious rats were
euthanized by intracardial injection of saturated KCl solution.
Statistical analysis
The data were processed using Prism Software version 5 (Graph
Pad, San Diego, U.S.A.). All values are expressed as means 6
SEM. While 2-tailed paired Student’s t-test was used to compare
two groups, One-way Analysis of Variance (ANOVA) followed by
a Tukey’s or Bonferoni’s Multiple comparison tests were applied to
determine the differences among multiple groups. The results were
considered statistically significant at p#0.05.
Results
TAT-Ahx-AKAPis peptide impaired endothelial barrier
properties in vitro
To study the role of AKAP-mediated PKA subcellular
anchoring for maintenance of endothelial barrier properties, we
used a cell-permeable synthetic peptide (TAT-Ahx-AKAPis)
designed to disrupt the endogenous PKA-AKAP complex [18].
Confluent microvascular endothelial cells were treated with TAT-
Ahx-AKAPis (30 mM) and subjected to continuous TER mea-
surements. In HDMEC, application of TAT-Ahx-AKAPis signif-
icantly decreased TER after 80 min incubation (80.462.04% of
baseline values) compared to control conditions (vehicle: 9261.2%
of baseline (p#0,01) and TAT-Ahx-mhK77:9061.93% of base-
line (p#0,05) (Figure 1, A). Microvascular murine MyEnd cells
responded similarly but slower to the inhibitory peptide (Figure
S1). Nonetheless, in both cell types, TAT-Ahx-AKAPis induced a
slowly progressive decrease in TER. In HDMEC, after 600 min of
application, values reached 5863%, whereas the values in control
cells treated with vehicle remained stable (10162.4%) (Figure 1, A
- B). In contrast, treatment with TAT-Ahx-mhK77 did not affect
TER in HDMEC (10062.0%) (Figure 1, A - B).
The AC activator forskolin and the PDE IV inhibitor rolipram
(F/R) increase cAMP levels and subsequently activate Rac1, the
latter was found to be at least in part required for maintenance of
endothelial barrier properties [7,29,34,35]. Thus, in line with
previous studies [29,36], treatment with F/R (5 mM/10 mM)
increased TER within 1 hour in both cell lines, with the effect
being more prominent in HDMEC. Within the first hour, F/R
rapidly increased TER in HDMEC (13965.6%) and remained
constantly elevated while in controls no significant changes were
detected (9261.2%). After 600 min, F/R reached its maximal
effect compared to control conditions with values being
14368.4% (Figure 1, A–B). Interestingly, in contrast to the
pretreatment with scrambled peptide (TAT-Ahx-mhK77), where
no significant alterations in the F/R effect (detected in control
conditions) were observed, pretreatment with the TAT-Ahx-
AKAPis inhibitory peptide diminished the F/R-mediated increase
in TER relative to control levels. This effect of TAT-Ahx-AKAPis
was also clearly detectable in MyEnd cells but again was evident
later (Figure S1). To further evaluate the effect of TAT-Ahx-
AKAPis on F/R- mediated endothelial barrier stabilization,
HDMEC monolayers treated for 1 hour with F/R were
subsequently subjected to TAT-Ahx-AKAPis peptide (Figure 1,
C). The analysis revealed that 1 hour after TAT-Ahx-AKAPis
application TER was similar in cells treated with F/R+TAT-Ahx-
AKAPis or F/R alone (F/R+TAT-Ahx-AKAPis: 12667%; FR:
12761%). However, starting 100 min after peptide addition TER
decline and after 230 min was comparable to experiments in
which cells were treated with TAT-Ahx-AKAPis alone (at
300 min: F/R+TAT-Ahx-AKAPis: 82.4610.7%; TAT-Ahx-
AKAPis: 7661.4%, Figure 1, C). Thus, the most significant peaks
of the monitored effects were determined at 1000 min, the time
point where similarly responding TAT-Ahx-AKAPis and F/R+
TAT-Ahx-AKAPis monolayers displayed TER significantly lower
than that of the control cells. In contrast, treatment of HDMEC
with F/R significantly increased TER compared to controls as
TER remained continuously elevated during the entire experi-
ment (Figure 1, D).
Taken together, these results indicate that TAT-Ahx-AKAPis
was sufficient to disrupt microvascular endothelial barrier prop-
erties, presumably via preventing AKAP-PKA complexation.
Additionally, post-treatment with TAT-Ahx-AKAPis reverted F/
R- mediated barrier stabilization whereas the pretreatment with
the synthetic peptide was uneffective to completely abolish the
barrier enhancing effect of F/R.
TAT-Ahx-AKAPis-induced endothelial barrier disruption
was paralleled by VE-cadherin reorganization and actin
cytoskeleton remodeling
Endothelial barrier functions are dependent on the organization
of junctional complex and the actin cytoskeleton [35]. Therefore,
possible alterations of these structures accompanying the TAT-
Ahx-AKAPis-induced decrease in TER were investigated by
immunofluorescence studies in HDMEC. Subsequently, measure-
ments of the fluorescence intensity along cell borders served to
quantitatively assess changes in the distribution of membrane
associated proteins. Beside the adherens junction protein VE-
cadherin, filamenteous (F-) actin, and PKA, stainings for AKAP12
and 220 were also performed. The AKAP 12 and 220 expression
profiles were initially evaluated by Western blot in human and
mouse microvascular endothelial cells (Figure 2, A and B). The
AKAPs in Endothelial Barrier Regulation
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Figure 2. Effects of PKA compartmentalization on adherens junctions, actin cytoskeleton and AKAP organization. To determine the
AKAPs protein expression profile, equal amounts of MyEnd and HDMEC cell lysates (20 mg per line) were subjected to WB analysis. The expression
patterns of AKAP220 (A) and AKAP12 (B) were analyzed. Loading was controlled by alpha tubulin expression. Data are representative of three or more
independent experiments (N$3). In addition, HDMEC monolayers were treated for 1 hour either with vehicle, TAT-Ahx-AKAPis, TAT-Ahx-mhK77, F/R
or with a combination of 1 hour TAT-Ahx-AKAPis pretreatment followed by 1 hour F/R application. The distributions of VE-cadherin, PKA, AKAP220
AKAPs in Endothelial Barrier Regulation
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analysis revealed more prominent expression of AKAPs in MyEnd
cells.
HDMEC monolayers were treated for 1 hour either with
vehicle solution, TAT-Ahx-AKAPis, corresponding scrambled
peptide or F/R. In addition, a regimen of 1 hour TAT-Ahx-
AKAPis pretreatment followed by 1 hour F/R application was
carried out. The cell monolayers incubated with vehicle solution
displayed slightly interdigitated but continuous VE-cadherin
staining along cell borders as well as few stress fibers localized
predominantly in cortical regions (Figure 2, C). Peripheral
membrane localization was partially visible for AKAP220,
AKAP12 and PKA (Figure 2, C, arrows). However, when
HDMEC were treated with TAT-Ahx-AKAPis, pronounced
reorganization of the actin cytoskeleton accompanied by enhanced
interdigitations and decreased staining intensity of VE-cadherin
were detectable (Figure 2, D, H). This was paralleled by
considerable reduction of PKA and AKAP220 but not AKAP12
membrane staining (Figure 2, D, I–K) indicating that at least in
the case of AKAP220 the peptide was effective in disrupting PKA
anchorage at sites of cell contacts. In contrast, the proteins under
investigation showed distributions similar to controls when
monolayers were treated with scrambled synthetic peptide
(Figure 2, E, H–K). Compared to controls, as reported previously
[26,29], F/R treatment resulted in more intense and linearized
VE-cadherin staining (Figure 2, F, H). Moreover, membrane
staining for AKAP12, AKAP220 and PKA was also more
pronounced (Figure 2, F, I–K). This was accompanied by
intensified cortical actin staining (Figure 2, F). In good agreement
with the TER data pre-incubation with the inhibitory peptide
interfered with the initial effect of F/R. HDMEC monolayers
appeared more similar to controls (Figure 2, G–K). In summary,
the above presented data showed that TAT-Ahx-AKAPis induced
reorganization of both endothelial adherens junctions and the
actin cytoskeleton as well as caused AKAP220 and PKA relocation
from the membrane.
In endothelial adherens junctions, VE-cadherin in addition to a
variety of structural proteins (i.e. ß-catenin, p120-catenin and
plakoglobin) associates with several molecules participating in
cAMP signaling such as PKA, PDE IV and Epac1 [37]. On the
other hand, it is well known that PKA is tethered by AKAP220
[38] and the latter was suggested to be connected to cytoskeletal
structures [39]. Therefore, we speculated that PKA via AKAP220
interacts with junctional complexes which may be required for
stabilization of the endothelial barrier. To test this hypothesis,
MyEnd lysates were subjected to immunoprecipitation. The
analysis confirmed a complex consisting of AKAP220, PKA, ß-
catenin and VE-cadherin. Both, pulling down VE-cadherin or
PKA, respectively, yielded the same results (Figure 3, A and B). In
addition, to monitor the changes in the complex composition as a
result of TAT-Ahx-AKAPis and/or F/R treatment, PKA pull-
down in lysates derived from cells treated either with synthetic
inhibitory peptide or with F/R was carried out. PKA pull-down in
cells subjected to scrambled peptide was used as respective control.
Compared to TAT-Ahx-mhK77 treatment, application of TAT-
Ahx-AKAPis reduced the band intensities for AKAP220 as well as
for VE-cadherin and ß-catenin indicating decreased association
with PKA. In contrast, F/R enhanced ß-catenin-, VE-cadherin-
and AKAP220- band intensities (Figure 3, C–D).
AKAP12 and AKAP220 are involved in regulation of
endothelial barrier function
To further investigate the role of AKAPs, the effect of
AKAP220- and AKAP12- specific depletion on endothelial barrier
function was determined and compared to treatment with TAT-
Ahx-AKAPis. Subconfluent MyEnd cells were transiently trans-
fected either with AKAP220- or AKAP12- specific siRNA or with
n.t siRNA, respectively. 24 hours after siRNA application, TER
measurements were initiated (Figure 4, A). The beginning of the
TER measurements was also the initial point of TAT-Ahx-
AKAPis peptide application. The experiments were continued for
additional 46 hours. The time window was estimated by Western
blot analysis validating the efficiency of the gene silencing in
MyEnd treated with AKAP-specific siRNAs (Figure 4 C, D).
Control cells transfected with n.t. siRNA increased TER over
time to values of 128.663.95% of baseline (Figure 4, A). In
contrast, siRNA-mediated AKAP12 and AKAP220 knockdown
initially decreased TER and subsequently abolished barrier
stabilization (10464.3% and 10863.6%, respectively). Similar,
but more significant was the effect upon TAT-Ahx-AKAPis
inhibitory treatment (9867.6%). Thus, these data indicate that
besides AKAP12 and AKAP220 possibly other AKAPs are
involved in the regulation of endothelial barrier function.
In order to estimate the effect on cAMP-mediated endothelial
barrier function, F/R was applied to cells either transiently
depleted of specific AKAPs or treated with n.t. siRNA (Figure 4,
B). The results indicate that depletion of AKAP12, but not of
AKAP220 significantly decreases the effect of cAMP-mediated
endothelial barrier stabilization. These data suggest that both
AKAPs alter endothelial barrier function but only AKAP12
modifies the subsequent cAMP-mediated endothelial barrier
enhancement.
Disruption of the PKA-AKAP endogenous complex
reduced Rac1 activity
Our data demonstrate that TAT-Ahx-AKAPis-mediated dis-
ruption of the endogenous PKA–AKAP complex attenuated
endothelial barrier functions under resting conditions. Since
cumulative evidence shows that cAMP governs microvascular
barrier properties, at least in part, in a Rac1-dependent manner
[35,40,41], we investigated the effect of TAT-Ahx-AKAPis on
Rac1 localization and activity. Immunofluorescence analysis in
HDMEC revealed that, under control conditions, Rac1 staining
and AKAP12 were assayed by immunofluorescence. Additionally, ALEXA-488-conjugated phalloidin was used for visualization of F-actin. (C) Under
control condition, VE-cadherin displayed slightly interdigitated but continuous staining along cell borders, and the actin cytoskeleton was
preferentially organized cortically. The staining of AKAP220, AKAP12 and PKA was detectable at cell borders (arrows). (D) In clear contrast, exposure to
TAT-Ahx-AKAPis increased interdigitations and significantly reduced the intensity of VE-cadherin staining. Profound reorganization of the actin
cytoskeleton was paralleled by substantial reduction of AKAP220 and PKA, but not of AKAP12 membrane staining. (E) However, cell monolayers
incubated with TAT-Ahx-mhK77 showed immunofluorescence staining similar to control for all proteins under investigation. (F) Not surprisingly, F/R
treatment resulted in pronounced and linearized VE-cadherin appearance, intensified cortical actin cytoskeleton, and pronounced membrane
staining for AKAP220, AKAP12 and PKA compared to control conditions. (G) 1 hour pre-incubation with TAT-Ahx-AKAPis followed by 1 hour
treatment with F/R resulted in monolayers largely similar to controls, but not to F/R incubation alone. Images are representative of three or more
independent experiments (N $3). Scale bar = 20 mm. The above presented data were confirmed by quantification of signal intensity distribution at
cell borders. (H–K) demonstrates the mean intensity peak observed at cell borders (n$15). *** p#0.001, ** p#0.01, * p#0.05, indicate statistically
significant difference between examined groups; n.s., not significant.
doi:10.1371/journal.pone.0106733.g002
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Figure 3. PKA and AKAP220 form a complex with junctional-associated proteins VE-cadherin and ß-catenin. A complex consisting of
PKA, ß-catenin, VE-cadherin and AKAP220 was detected in MyEnd either by pulling down VE-cadherin (A) or PKA (B). Immunoprecipitated proteins
and their binding partners were detected in the lysates used for immunoprecipitation. The lysates were loaded at the first lane and denoted as an
‘‘Input’’. Immunoprecipitation without antibody (IP: Beads, no Ab) was used as a negative control. Every other lane represents proteins in complex
under different experimental conditions. (C) To test the role of PKA compartmentalization on the stability of the determined complex, PKA pull down
was performed in cells treated either with inhibitory or with the respective scrambled peptide. Additionally, the effect of F/R on complex stability was
analyzed. (D) summarizes data collected from three independent immunoprecipitation experiments. Firstly, intensity readings for each band were
background corrected. Secondly, data was modified by substraction of ‘‘non-specific background intensities’’ detected in IP without Ab (negative
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was in part detectable along cell borders, (Figure 5, A, arrows).
Such membrane localization of Rac1 was previously correlated
with an increase in its activity. In this respect, our previous study
showed that constitutively active Rac1 localized to cell- cell
borders in endothelial cells whereas this effect was not observed in
cells transfected with dominant negative Rac1 [42]. However,
strong reduction of Rac1 membrane staining and relocation to the
cytoplasm were detected after TAT-Ahx-AKAPis application
(Figure 5, C). Further densitometric assessment of the immuno-
fluorescent data confirmed these observations (Figure 5, E).
Consistently, Rac1 rearrangement was paralleled by altered
GTPase activity in HDMEC and MyEnd cells as measured by
G-LISA Rac activation assay (Figure 5 F–G). However, treatment
with TAT-Ahx-mhK77 neither showed changes in Rac1 localiza-
tion nor in Rac1 activity when compared to control condition
(Figure 5, B, E–G). In contrast, application of F/R dramatically
control). Since PKA was used to pull-down the complex, signal intensity of the immunoprecipitated proteins was normalized to the band intensity of
PKA (represented as fold changes of PKA staining intensity). As a final, the data was presented as percent of IP: PKA, TAT-Ahx-mhK77. The analysis
revealed decreased complex association of ß-catenin, VE cadherin and AKAP220 after TAT-Ahx-AKAPis treatment. In contrast, F/R application led to
stabilization of the complex indicated by more prominent intensities for bands representing ß-catenin, VE-cadherin and AKAP220. Noncontiguous
bands run on the same gel are separated by a black line. Images are representative of three independent experiments (N= 3).
doi:10.1371/journal.pone.0106733.g003
Figure 4. siRNA-mediated AKAP12 and AKAP220 knockdown significantly impaired endothelial barrier function. (A) Barrier function
of subconfluent MyEnd cells was monitored by TER measurements following transfection with siRNA specific for AKAP12 and AKAP220. Non-
targeting siRNA was used as a control. The results were compared to cells treated with TAT-Ahx-AKAPis inhibitory peptide. AKAP12 and AKAP220
depletion lead to a significant decrease in TER compared to monolayers transfected with n.t. siRNA. Similar, but more prominent, was the effect
obtained after TAT-Ahx-AKAPis application. Data were collected from three or more independent experiments (N $3, n $12). (B) To test the role of
specific AKAPs on cAMP-mediated endothelial barrier formation, TER measurements in cells treated with F/R, 48 hours after successful AKAP-
depletion were performed; (n$10). (C) AKAP12 and AKAP220 knockdown was confirmed by Western blot, 48 hours after transfection. ß-actin was
used as an internal gel-loading control. (D) Western blot data were analyzed densitometrically. Normalized intensities for AKAP signals are presented
as a bar graph. Data were collected from more than three independent experiments (N $3). * p#0.05, **p#0.01 and ***p#0.001 indicate statistically
significant difference between the examined group and n.t. siRNA; # p#0.05 shows statistically significant difference between AKAP12 siRNA and
AKAP220 siRNA upon treatment with F/R. The difference was significant starting at 1500 min.
doi:10.1371/journal.pone.0106733.g004
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enriched the staining of Rac1 at the membrane (Figure 5, D–E).
Consistent with the immunofluorescence analysis, F/R caused a
significant increase of Rac1 activity in both cell types (for
HDMEC, F/R: 14865% and for MyEnd, F/R: 139614%;
Figure 5 F–G). In HDMEC, the latter was approximately 48%
more than the activity determined in controls or scrambled-treated
cells (vehicle: 100%; TAT-Ahx-mhK77:9963%). The effect in
MyEnd cells was similar, but slightly smaller (more than 33%),
(vehicle: 100%; scrambled: 10563% (n.s.)). ELISA-based Rac1
activity measurements also demonstrated that peptide-application
significantly reduced Rac1 activity to 8362% of control conditions
in HDMECs and 7166% in MyEnd cells (Figure 5 F–G).
To further evaluate the effect of specific AKAPs on Rac1
activity, we silenced AKAP12 or AKAP220 by siRNA and
assessed Rac1 activity 48 hours after knockdown in MyEnd cells.
Neither down-regulation of AKAP12 and/or AKAP220 mRNA
alone nor parallel silencing of both AKAPs altered basal Rac1
activity (Figure 6, A). Nevertheless, cAMP-mediated Rac1 activa-
tion was significantly reduced in cells simultaneously depleted for
AKAP12 and AKAP220 but not in cells in which only one of the
two AKAPs was silenced (Figure 6, A). Effective mRNA down-
regulation was validated by Western blot (Figure 6, B).
Figure 5. TAT-Ahx-AKAPis reduced Rac1 activity. HDMEC monolayers grown on glass coverslips were subjected to immunostaining with anti-
Rac1 antibody. (A) In controls, Rac1 was partially present along cell borders (arrows). (B) Similar Rac1 staining was observed after application of TAT-
Ahx-mhK77. (C) In contrast, treatment with TAT-Ahx-AKAPis strongly reduced Rac1 membrane staining and induced re-localization of the molecule to
the cytoplasm. (D) However, the cAMP enhancers F/R led to pronounced and intensified Rac1 membrane staining. Images are representative of three
or more experiments (N$3). Scale bar = 20 mm. (E) Quantification of the signal intensity distributed along cell-cell junctions supported the above
mentioned observations. In order to summarize all experiments, data were presented as percent of control (N$3̧n$10). (F) In HDMEC, ELISA-based
measurements revealed a significant decrease of Rac1 activity in response to 1 hour treatment with TAT-Ahx-AKAPis. Application of F/R also
significantly increased Rac1 activity when compared to control. As expected, TAT-Ahx-mhK77 administration had no effect on Rac1 activity. (G) The
effects observed in MyEnd cells were similar. In agreement with TER, the effect of TAT-Ahx-AKAPis inhibitory peptide was evident later. Therefore, the
MyEnd samples were collected 6 hours after peptide application. The results are representative of three independent experiments (N = 3, n $6). *
defines statistically significant difference; * p#0.05, ** p#0.05, *** p#0.001. n.s. not significant.
doi:10.1371/journal.pone.0106733.g005
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TAT-Ahx-AKAPis treatment increased hydraulic
conductivity (Lp) of single perfused rat postcapillary
venules in vivo
To investigate whether the application of TAT-Ahx-AKAPis
also affects microvascular barrier properties in vivo, we applied
the single microvessel perfusion technique [27] in rat mesentery
postcapillary venules. Intact microvessels were constantly perfused
either with TAT-Ahx-AKAPis or with vehicle solution and
hydraulic conductivity was measured every 10 min. No significant
Lp differences of TAT-Ahx-AKAPis-treated and control vessels
were monitored within the first 60 min (Figure 7, A and B).
However, Lp increased starting 60 min after TAT-Ahx-AKAPis
addition. After 120 min of treatment, Lp of TAT-Ahx-AKAPis-
perfused vessels reached a mean value of 4.5760.9161027 [cm/
(s6cm H2O)]) which was significantly higher compared to controls
(2.5360.4761027 [cm/(s6cm H2O)]), (Figure 7, B). Thus, TAT-
Ahx-AKAPis impaired microvascular endothelial barrier proper-
ties both in vivo and in vitro.
Discussion
The goal of the current report was to study in more details the
mechanisms underlying cAMP-mediated regulation of endothelial
barrier properties. Specifically, we examined the functional
relevance of AKAPs which on one hand are well established to
tightly regulate PKA function by facilitating its discrete cellular
compartmentalization, and on the other hand are known to form
multivalent complexes to integrate cAMP signaling with various
other pathways. We provided evidence that AKAPs are required
for maintenance of microvascular endothelial barrier integrity
both in vivo and in vitro under resting conditions. We also
showed that under resting conditions AKAPs are relevant for
correct signal transduction because Rac1 activity was decreased
following inhibition of PKA-AKAP anchoring. Particularly, we
also found that AKAP12 and AKAP220 are involved in regulation
of endothelial barrier function. Further examinations revealed that
simultaneous down-regulation of AKAP12 and AKAP220 expres-
sion impaired F/R-mediated Rac1 activation. We also demon-
strated that AKAP12, but not AKAP220, is important for
subsequent cAMP-mediated endothelial barrier improvement.
Finally, we showed that AKAP220 forms a complex with PKA,
Figure 6. Simultaneous knockdown of AKAP12 and AKAP220 mRNA impaired cAMP-mediated Rac1 activation. (A) Subconfluent
monolayers of MyEnd cells were transfected either with single AKAP siRNA or with a pool of AKAP12 and AKAP220 specific siRNAs. Basal Rac1 activity
was tested 48 hours after initial siRNA depletion. For evaluation of cAMP-mediated Rac1 activation, transfected cells were subjected to F/R for 1 hour.
Non-target siRNA (n.t. siRNA) alone or in combination with F/R (1 hour) was used as a respective control. Bars represent mean values 6 SEM. Basal
activity of Rac1 was unaffected after single or combined silencing of AKAPs. In contrast, cAMP-mediated Rac1 activation was significantly impaired
following simultaneous AKAP12 and AKAP220 mRNA knockdown. (B) Successful knockdown was verified by Western blot 48 hours after initial siRNA
transfection; ß-actin was used as an internal gel-loading control. ** indicates p#0.01 versus cells transfected with n.t. siRNA treated for an hour with
F/R.
doi:10.1371/journal.pone.0106733.g006
AKAPs in Endothelial Barrier Regulation
PLOS ONE | www.plosone.org 11 September 2014 | Volume 9 | Issue 9 | e106733
ß-catenin and VE-cadherin, and therefore can spatially link cAMP
signaling to endothelial adherens junctions.
cAMP signaling needs to be compartmentalized to exert
barrier protective effects
cAMP is well established to be important for barrier formation
and maintenance [7,33]. Furthermore, a variety of barrier
destabilizing mediators decrease cAMP levels leading to increased
permeability [26,31,43]. This decrease in cAMP can be initiated
by a rapid Ca2+-influx [26,33,44] which subsequently may inhibit
AC activity [45]. Downstream of cAMP, Rac1 is an important
signaling molecule for barrier stabilization [7,35,46]. Two distinct
signaling pathways involving on one hand PKA and on the other
hand Epac1/Rap1 have been shown to merge on and activate
Rac1 [47]. Rac1 via a plethora of mechanisms [35,40,46] induces
cortical actin remodeling and reorganization of intercellular
junctions which ultimately affects paracellular permeability
[1,34]. Not surprisingly, it is important where in the cell cAMP
is generated in order to provide barrier protective effects [48].
cAMP generated by membrane-attached ACs is protective,
whereas cAMP increased by a soluble AC is not. The latter in
contrast increases permeability [49]. Thus, to provide distinct
effects, cAMP signaling needs to be tightly regulated in space and
time. Beside ACs, other key players involved in this regulation are
PDEs, which locally hydrolyze cAMP [50]. Similarly, AKAPs
facilitate compartmentalization of PKA signaling downstream of
cAMP. Our data provide a mechanism, by which the function of
PKA can be directed to cell junctions.
AKAPs are essential for maintenance and stabilization of
endothelial barrier properties
Under resting conditions, TAT-Ahx-AKAPis destabilized bar-
rier functions both in vitro and in vivo. This effect was
qualitatively similar in two microvascular cell types and postcap-
illary venules, indicating that AKAP function is an important
factor for endothelial barrier maintenance. Similar to our
observation, a recent study demonstrated that low expression of
AKAP12 may lead to blood-retinal barrier dysfunction [21].
Further investigations in this direction reported the role of
AKAP12 in maintenance of the vascular integrity by modulation
of the actin cytoskeleton dynamic through PAK2 and AF6 [20].
Another member of the AKAP-family, i.e. AKAP9 was also
discovered to be required for microtubule growth, integrin
adhesion at cell-cell borders and endothelial barrier function via
Epac1-dependent pathway [51]. Thus, besides PKA, AKAPs can
also be associated with Epac1 [51,52]. Therefore, AKAPs may
serve as coordinators not only of PKA- but also of Epac1- induced
regulation of endothelial barrier properties [52].
Furthermore, we found that inhibition of AKAP function via
TAT-Ahx-AKAPis also interfered with barrier stabilization in
response to increased cAMP. In HDMEC, this approach was
effective to revert F/R-induced barrier stabilization. In line with
that, earlier we reported that incubation with a cell permeable
PKA inhibitor blocked the F/R-mediated increase in TER [36].
Herein, we also showed that depletion of AKAP12 but not of
AKAP220 significantly decreased cAMP-mediated endothelial
barrier integrity as examined by TER (Figure 4). Moreover,
simultaneous depletion of AKAP12 and AKAP220 but not of a
single AKAP impaired cAMP-mediated Rac1 activation (Figure 6)
which is indicative for a redundant function of those AKAPs in the
regulation of Rac1 activity. Taken together, these results also
demonstrate that AKAP12 may interfere with cAMP-mediated
endothelial barrier stabilization in a manner which at least in part
is independent of Rac1 (because AKAP12 down- regulation did
not alter Rac1 activation). In agreement with this presumption is
our recent study revealing that F/R- induced Rac1 activation and
barrier augmentation were not affected by the Rac1 inhibitor
NSC-23766. Therefore, we argue that GTPases other than Rac1
may also account for the F/R- induced enhancement of
endothelial barrier properties [34]. Additionally, one can speculate
that besides Rac1, AKAP12 may take part in different cAMP-
induced signaling pathways involved in endothelial barrier
stabilization. In this respect, a recent study determined AKAP12
molecule as a dynamic platform for signal transduction complex-
ing a number of signaling molecules such as PKA, PKC,
calmodulin, F- actin and ß-adrenergic receptors [53].
Similar to AKAP12, we also showed that depletion of
AKAP220 impaired the function of the endothelial barrier in
MyEnd cells. However, the effect of silencing specific AKAPs was
less prominent than the one observed upon TAT-Ahx-AKAPis
application (Figure 4). This supports the idea that several AKAPs
Figure 7. TAT-Ahx-AKAPis application increased hydraulic conductivity (Lp) in rat mesenteric microvessels in vivo. Hydraulic
conductivity (Lp) of isolated post-capillary microvessels from rat mesentery was monitored over time. (A) displays data from a representative vessel
constantly perfused either with vehicle or with TAT-Ahx-AKAPis. (B) Bar diagram summarizes the mean values of all five independent experiments.
120 min after TAT-Ahx-AKAPis perfusion, Lp was significantly increased to 4.5760.91610
27 [cm/(s6cm H20)] compared to the corresponding vehicle
condition (2.5360.4761027 [cm/(s6cm H20)]). *indicates p#0.05 versus control condition; N= 5.
doi:10.1371/journal.pone.0106733.g007
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including AKAP220 and AKAP12 are involved in modulation of
endothelial barrier function.
AKAP220 contributed to endothelial barrier integrity by
forming a multivalent complex that links cAMP signaling
to adherens junctions
Besides PKA anchoring, several AKAPs were found to act as
scaffolding proteins thereby participating in various signal
transduction processes. Formation of multivalent complexes
provides a high level of specificity and temporal regulation to
cAMP/PKA signaling [17]. As mentioned above, we examined
the role of AKAP220 which was already reported to organize
multivalent complexes. In this respect, AKAP220 was shown to
form a complex with IQGAP1 and E-cadherin in MCF-7 cells and
to link cAMP signaling to cell adhesion [25]. Furthermore, recent
investigations provided evidence that AKAP220 forms a complex
with IQGAP2 that favors PKA-dependent recruitment of Rac1 to
strengthen cortical actin [24]. Thus, AKAP220 not only provides
substrate specificity by tight subcellular localization of PKA, but
also regulates and restricts the activity of several effectors which
are part of this complex [24,54,55,56]. Similar to AKAP79/150,
which was found to localize on the cell membrane and to assemble
a ternary complex with E-cadherin and ß-catenin in epithelial cells
[57], we detected AKAP220 to co-immunoprecipitate with VE-
cadherin and ß-catenin as well as to localize at cell borders similar
to VE-cadherin, PKA and Rac1 in microvascular endothelial cells
(Figure 2 and 3). Moreover, we demonstrated that F/R- mediated
endothelial barrier stabilization was paralleled by increased
membrane localization and association of PKA with AKAP220
and VE-cadherin in a complex. The latter observations are
consistent with the idea that cAMP via PKA may allow
compartmentalized Rac1 activation close to adherens junctions
and the cortical actin cytoskeleton. This may be physiologically
relevant because TAT-Ahx-AKAPis induced prominent cytoskel-
etal rearrangement and VE-cadherin interdigitation under condi-
tions of a destabilized endothelial barrier. These effects were
associated with decreased PKA, AKAP220, and Rac1 membrane
staining, as well as reduced Rac1 activity (Figure 2 and 5).
Additionally, TAT-Ahx-AKAPis decreased the association of
AKAP220, VE-cadherin and ß-catenin with PKA demonstrating
that AKAPs are required to localize PKA to endothelial adherens
junctions (Figure 3). Consistent with our assumptions is a study
demonstrating that PKA, Epac1, PDE4D and AKAP79 are
recruited to VE-cadherin-based complexes in response to cell-cell-
contact formation [37].
In conclusion, we showed that AKAPs, and specifically
AKAP12 and AKAP220, contribute to regulation of microvascu-
lar endothelial barrier function in Rac1- dependent and –
independent manner. Our data also indicate that AKAP220
forms a multivalent protein complex linking cAMP signaling to
adherens junctions.
Supporting Information
Figure S1 TAT-Ahx-AKAPis interfered with endothelial
barrier function in MyEnd cells. (A) shows TER time courses
for different conditions applied in MyEnd cell monolayers. In
comparison to control and TAT-Ahx-mhK77- treated endothelial
cells, monolayers subjected to TAT-Ahx-AKAPis significantly
decreased TER over time. The effect was slower than in HDMEC
cells but prominent approximately 600 min after initial applica-
tion. Moreover, in vehicle and TAT-Ahx-mhk77- treated
monolayers F/R application led to a progressive TER increase
over time. In contrast, TER in TAT-Ahx-AKAPis- pretreated
monolayers transiently increased after addition of F/R but
declined afterwards to finally reach values similar to control
conditions after 450 min. (B) outlines the results after 800 min, the
time point at which the monitored effects reached their peaks.
Data were collected from more than three independent experi-
ments (N $3). * p#0.05 and *** p#0.001 indicate statistically
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